MXPA05008394A - Uso de la familia de genes sgk para el diagnostico y terapia de cataratas y glaucoma. - Google Patents
Uso de la familia de genes sgk para el diagnostico y terapia de cataratas y glaucoma.Info
- Publication number
- MXPA05008394A MXPA05008394A MXPA05008394A MXPA05008394A MXPA05008394A MX PA05008394 A MXPA05008394 A MX PA05008394A MX PA05008394 A MXPA05008394 A MX PA05008394A MX PA05008394 A MXPA05008394 A MX PA05008394A MX PA05008394 A MXPA05008394 A MX PA05008394A
- Authority
- MX
- Mexico
- Prior art keywords
- glaucoma
- diagnosis
- diabetic neuropathy
- cataract
- cataracts
- Prior art date
Links
- 208000002177 Cataract Diseases 0.000 title abstract 5
- 208000010412 Glaucoma Diseases 0.000 title abstract 5
- 238000003745 diagnosis Methods 0.000 title abstract 3
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 4
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 238000013518 transcription Methods 0.000 abstract 1
- 230000035897 transcription Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
- G01N2800/166—Cataract
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
- G01N2800/168—Glaucoma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- General Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10305212A DE10305212A1 (de) | 2003-02-07 | 2003-02-07 | Verwendung der sgk-Genfamilie zur Diagnose und zur Therapie von Katarakt und Glaukom |
| PCT/EP2004/001048 WO2004069258A2 (de) | 2003-02-07 | 2004-02-05 | Verwendung der sgk-genfamilie zur diagnose und zur therapie von katarakt und glaukom |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05008394A true MXPA05008394A (es) | 2005-10-05 |
Family
ID=32730900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05008394A MXPA05008394A (es) | 2003-02-07 | 2004-02-05 | Uso de la familia de genes sgk para el diagnostico y terapia de cataratas y glaucoma. |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1663246A2 (enExample) |
| JP (1) | JP2006519189A (enExample) |
| KR (1) | KR20050114214A (enExample) |
| CN (1) | CN1771039A (enExample) |
| AU (1) | AU2004210416A1 (enExample) |
| BR (1) | BRPI0407300A (enExample) |
| CA (1) | CA2514703A1 (enExample) |
| DE (1) | DE10305212A1 (enExample) |
| MX (1) | MXPA05008394A (enExample) |
| PL (1) | PL378399A1 (enExample) |
| RU (1) | RU2005127808A (enExample) |
| WO (1) | WO2004069258A2 (enExample) |
| ZA (1) | ZA200506280B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070191326A1 (en) * | 2004-03-11 | 2007-08-16 | Florian Lang | Methods for modulating glutamate receptors for treating neuropsychiatric disorders comprising the use of modulators of serum and glucocorticoid inducible kinases |
| US20070203085A1 (en) * | 2004-03-11 | 2007-08-30 | Florian Lang | Methods For Interfering With Fibrosis |
| DE102004059781A1 (de) * | 2004-12-10 | 2006-06-22 | Sanofi-Aventis Deutschland Gmbh | Verwendung der Serum-/Glucocorticoid regulierten Kinase |
| US20060293378A1 (en) * | 2005-06-28 | 2006-12-28 | Mcintire Gregory | Method of lowering intraocular pressure |
| WO2007037560A1 (ja) * | 2005-09-30 | 2007-04-05 | Link Genomics, Inc. | Ｓｇｋ２遺伝子の治療的又は診断的用途 |
| AU2006318550A1 (en) * | 2005-11-22 | 2007-05-31 | Mcgill University | Intraocular pressure-regulated early genes and uses thereof |
| WO2008079980A1 (en) * | 2006-12-22 | 2008-07-03 | Alcon Research, Ltd. | Inhibitors of protein kinase c-delta for the treatment of glaucoma |
| DE102008029072A1 (de) * | 2008-06-10 | 2009-12-17 | Lang, Florian, Prof. Dr.med. | Sgk3 als therapeutisches und diagnostisches Target für Alterserkrankungen |
| EP2667885B1 (en) * | 2011-01-25 | 2018-08-08 | Monell Chemical Senses Center | Compositions and methods for providing or modulating sweet taste and methods of screening therefor |
| KR102357260B1 (ko) * | 2020-12-10 | 2022-02-08 | 주식회사 레피겐엠디 | 마이크로rna를 이용한 당뇨병성 신경병증의 예측 및 진단 방법 및 이를 위한 키트 |
| CN119303113A (zh) * | 2024-09-03 | 2025-01-14 | 河北大学附属医院 | Nedd4l基因在制备治疗血管内皮细胞增生性相关疾病药物中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69535673D1 (de) * | 1994-08-30 | 2008-02-07 | Univ Dundee | Mittel zur induktion von apoptosis und zur therapieanwendung |
| CA2222562A1 (en) * | 1995-06-07 | 1996-12-19 | Jeffrey N. Miner | Method for screening for receptor agonists and antagonists |
| US5925523A (en) * | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
| DE19708173A1 (de) * | 1997-02-28 | 1998-09-03 | Dade Behring Marburg Gmbh | Zellvolumenregulierte humane Kinase h-sgk |
| AU3991499A (en) * | 1998-05-15 | 1999-12-06 | Joslin Diabetes Center | Independent regulation of basal and insulin-stimulated glucose transport |
| WO2000035946A1 (en) * | 1998-12-14 | 2000-06-22 | The University Of Dundee | Methods |
| US6399655B1 (en) * | 1998-12-22 | 2002-06-04 | Johns Hopkins University, School Of Medicine | Method for the prophylactic treatment of cataracts |
| DE19917990A1 (de) * | 1999-04-20 | 2000-11-02 | Florian Lang | Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk |
| AU5840300A (en) * | 1999-07-14 | 2001-01-30 | University Of Lausanne | Glutx polypeptide family and nucleic acids encoding same |
| US6416759B1 (en) * | 1999-09-30 | 2002-07-09 | The Regents Of The University Of California | Antiproliferative Sgk reagents and methods |
| US20030236246A1 (en) * | 2002-04-30 | 2003-12-25 | Brazzell Romulus Kimbro | Method for decreasing capillary permeability in the retina |
| DE10225844A1 (de) * | 2002-06-04 | 2003-12-18 | Lang Florian | sgk und nedd als diagnostische und therapeutische targets |
-
2003
- 2003-02-07 DE DE10305212A patent/DE10305212A1/de not_active Withdrawn
-
2004
- 2004-02-05 CA CA002514703A patent/CA2514703A1/en not_active Abandoned
- 2004-02-05 CN CNA2004800070348A patent/CN1771039A/zh active Pending
- 2004-02-05 MX MXPA05008394A patent/MXPA05008394A/es unknown
- 2004-02-05 AU AU2004210416A patent/AU2004210416A1/en not_active Abandoned
- 2004-02-05 RU RU2005127808/15A patent/RU2005127808A/ru not_active Application Discontinuation
- 2004-02-05 PL PL378399A patent/PL378399A1/pl not_active Application Discontinuation
- 2004-02-05 BR BR0407300-2A patent/BRPI0407300A/pt not_active IP Right Cessation
- 2004-02-05 EP EP04708350A patent/EP1663246A2/de not_active Withdrawn
- 2004-02-05 WO PCT/EP2004/001048 patent/WO2004069258A2/de not_active Ceased
- 2004-02-05 KR KR1020057014582A patent/KR20050114214A/ko not_active Withdrawn
- 2004-02-05 JP JP2006501737A patent/JP2006519189A/ja active Pending
-
2005
- 2005-08-05 ZA ZA200506280A patent/ZA200506280B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2514703A1 (en) | 2004-08-19 |
| ZA200506280B (en) | 2006-05-31 |
| WO2004069258A3 (de) | 2005-02-24 |
| KR20050114214A (ko) | 2005-12-05 |
| RU2005127808A (ru) | 2006-05-27 |
| PL378399A1 (pl) | 2006-04-03 |
| WO2004069258A2 (de) | 2004-08-19 |
| DE10305212A1 (de) | 2004-08-19 |
| AU2004210416A1 (en) | 2004-08-19 |
| CN1771039A (zh) | 2006-05-10 |
| BRPI0407300A (pt) | 2006-02-07 |
| EP1663246A2 (de) | 2006-06-07 |
| JP2006519189A (ja) | 2006-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Goodman et al. | Toxic expanded GGGGCC repeat transcription is mediated by the PAF1 complex in C9orf72-associated FTD | |
| EP2820131A2 (de) | Verwendung von micrornas oder genen als marker zur identifizierung, diagnose und therapie einzelner formen nicht-ischämischer kardiomyopathien oder speichererkrankungen des herzens | |
| WO2004069258A3 (de) | Verwendung der sgk-genfamilie zur diagnose und zur therapie von katarakt und glaukom | |
| Scholz et al. | Dependency of intraocular pressure elevation and glaucomatous changes in DBA/2J and DBA/2J-Rj mice | |
| Kosior-Jarecka et al. | MicroRNAs in the aqueous humor of patients with different types of glaucoma | |
| Jiang et al. | The role of microRNAs in myopia | |
| US20180318285A1 (en) | Methods for treatment of autism spectrum disorders | |
| Winkler et al. | Fuchs' endothelial corneal dystrophy in patients with myotonic dystrophy, type 1 | |
| US20250043281A1 (en) | Treatment of fgg related diseases and disorders | |
| Wijesinghe et al. | MicroRNAs in tear fluids predict underlying molecular changes associated with Alzheimer’s disease | |
| Shi et al. | miR-9 regulates basal ganglia-dependent developmental vocal learning and adult vocal performance in songbirds | |
| Wang et al. | Dysregulation of antimicrobial peptide expression distinguishes Alzheimer’s disease from normal aging | |
| JP7244437B2 (ja) | 円錐角膜に関連する対立遺伝子を検出する方法 | |
| Liu et al. | Silencing microRNA-29b-3p expression protects human trabecular meshwork cells against oxidative injury via upregulation of RNF138 to activate the ERK pathway | |
| JP5769084B2 (ja) | Ｃａｇ伸長遺伝子産物の発現および遺伝子産物の発現および凝集を抑制するための方法、ならびに同様に抑制するために有用である薬剤を特定するための方法 | |
| CN108354944A (zh) | siRNA及其在用于治疗和/或预防眼部病症的方法和组合物中的应用 | |
| Sohn et al. | Genetic association between MMP9 and choroidal neovascularization in age-related macular degeneration | |
| Ayada | Evaluation of whether the ACE gene I/D polymorphism constitutes a risk factor for chronic obstructive pulmonary disease in the Turkish population | |
| Prasad | Genes for endosomal pH regulators NHE6 and NHE9 are dysregulated in the substantia nigra in Parkinson’s disease | |
| Ambler et al. | Microarray expression profiling in adhesion and normal peritoneal tissues | |
| Rampazzo et al. | Hormographiella aspergillata keratomycosis in a dog | |
| Sharma et al. | Does toll-like receptor-3 (TLR-3) have any role in Indian AMD phenotype? | |
| Li et al. | Divergent impacts of C9orf72 repeat expansion on neurons and glia in ALS and FTD | |
| SE0002189D0 (sv) | New method and assay | |
| Liu et al. | Methylome profiling reveals epigenetic alterations in the trabecular meshwork of primary open-angle glaucoma |